← Back to Screener
Silence Therapeutics Plc American Depository Share (SLN)
Price$7.60
Favorite Metrics
Price vs S&P 500 (26W)-36.42%
Price vs S&P 500 (4W)56.47%
Market Capitalization$343.86M
All Metrics
Book Value / Share (Quarterly)$0.44
P/TBV (Annual)26.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)315.49%
Price vs S&P 500 (YTD)13.22%
Gross Margin (TTM)61.39%
Net Profit Margin (TTM)-14408.15%
EPS (TTM)$-0.63
10-Day Avg Trading Volume0.00M
EPS Excl Extra (TTM)$-0.63
Revenue Growth (5Y)305.31%
ROI (Annual)-48.53%
Gross Margin (Annual)37.83%
Net Profit Margin (5Y Avg)-422.12%
Cash / Share (Quarterly)$0.08
Revenue Growth QoQ (YoY)-99.92%
ROA (Last FY)-39.75%
Revenue Growth TTM (YoY)-99.27%
EBITD / Share (TTM)$-0.57
ROE (5Y Avg)-135.82%
Operating Margin (TTM)-15028.30%
Cash Flow / Share (Annual)$-0.52
P/B Ratio5.52x
P/B Ratio (Quarterly)4.66x
Net Income / Employee (Annual)$-490,658
EV / Revenue (TTM)797.57x
Net Interest Coverage (TTM)-15.11x
ROA (TTM)-56.37%
EPS Incl Extra (Annual)$-0.53
Current Ratio (Annual)4.46x
Quick Ratio (Quarterly)8.06x
3-Month Avg Trading Volume0.00M
52-Week Price Return-72.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.44
P/S Ratio (Annual)20.61x
Asset Turnover (Annual)0.17x
52-Week High$2.60
Operating Margin (5Y Avg)-486.99%
EPS Excl Extra (Annual)$-0.53
CapEx CAGR (5Y)149.02%
Tangible BV CAGR (5Y)-20.87%
26-Week Price Return-31.07%
13-Week Price Return7.05%
Total Debt / Equity (Annual)2.02x
Current Ratio (Quarterly)8.72x
Enterprise Value$332.586
Revenue / Share Growth (5Y)279.98%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-22.83%
Revenue / Employee (Annual)$212,082
Pretax Margin (Annual)-270.66%
Cash / Share (Annual)$0.83
Net Income / Employee (TTM)$-1
ROE (Last FY)-264.65%
Net Interest Coverage (Annual)-5.50x
EPS Basic Excl Extra (Annual)$-0.53
Receivables Turnover (TTM)0.86x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.63
Receivables Turnover (Annual)28.09x
ROI (TTM)-103.26%
P/S Ratio (TTM)824.61x
Pretax Margin (5Y Avg)-484.47%
Revenue / Share (Annual)$0.23
Tangible BV / Share (Annual)$0.16
Price vs S&P 500 (52W)-75.27%
Year-to-Date Return20.00%
5-Day Price Return50.00%
EPS Normalized (Annual)$-0.53
ROA (5Y Avg)-43.18%
Net Profit Margin (Annual)-231.35%
Month-to-Date Return20.00%
Cash Flow / Share (TTM)$-0.33
Operating Margin (Annual)-277.66%
LT Debt / Equity (Annual)1.19x
ROI (5Y Avg)-53.35%
LT Debt / Equity (Quarterly)0.57x
EPS Basic Excl Extra (TTM)$-0.63
P/TBV (Quarterly)4.68x
P/B Ratio (Annual)3.53x
Pretax Margin (TTM)-14405.52%
Book Value / Share (Annual)$0.26
Price vs S&P 500 (13W)3.44%
Beta2.98x
Revenue / Share (TTM)$0.00
ROE (TTM)-103.26%
52-Week Low$0.50
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SLNSilence Therapeutics Plc American Depository Share | 824.61x | -99.27% | 61.39% | — | $7.60 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Silence Therapeutics is a biotechnology company developing short-interfering RNA (siRNA) therapeutics using its proprietary mRNAi GOLD platform. The company's pipeline targets cardiovascular disease, hematology, and rare diseases, with lead candidates Divesiran for hematological disorders and Zerlasiran for cardiovascular conditions. Silence also generates revenue through out-licensed programs with third-party collaborators.